We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Surrozen Inc (SRZN) USD0.0001

Sell:$7.25 Buy:$15.90 Change: $0.1 (0.70%)
Market closed |  Prices as at close on 2 January 2025 | Switch to live prices |
Sell:$7.25
Buy:$15.90
Change: $0.1 (0.70%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 2 January 2025 | Switch to live prices |
Sell:$7.25
Buy:$15.90
Change: $0.1 (0.70%)
Market closed |  Prices as at close on 2 January 2025 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Surrozen, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a range of organs and tissues. The Company is developing tissue-specific antibodies designed to engage the body’s existing biological repair mechanisms with a current focus on severe liver and eye diseases. Its two lead product candidates include SZN-043 and SZN-413. SZN-043 is the first development candidate using Surrozen’s SWEETS technology. It is developing SZN-043 for severe liver diseases, initially focusing on alcohol-associated hepatitis. It has completed Phase I a clinical trial in patients with chronic liver disease and healthy volunteers. SZN-413 is a bi-specific antibody targeting Fzd4-mediated Wnt signaling designed using Surrozen’s SWAP technology. SZN-413 is being developed for the treatment of retinal vascular-associated diseases.

Contact details

Address:
171 Oyster Point Blvd, Suite 400
SOUTH SAN FRANCISCO
94080
United States
Telephone:
+1 (650) 4752820
Website:
https://www.surrozen.com

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
SRZN
ISIN:
US86889P2083
Market cap:
$46.63 million
Shares in issue:
3.25 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Craig Parker
    President, Chief Executive Officer, Director
  • Charles Williams
    Chief Financial Officer, Chief Operating Officer, Company Secretary
  • Yang Li
    Executive Vice President - Research

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.